MetaVia Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Hyung Heon Kim
- Full Time Employees
- 9
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 545 Concord Avenue Cambridge MA United States of America 02138
- IPO Date
- Aug 5, 2016
- CIK
- 0001638287
- Website
- metaviatx.com
- Similar Companies
- Business
- MetaVia Inc. (Nasdaq: MTVA) is a clinical-stage biotechnology company focused on developing novel pharmaceuticals to treat cardiometabolic diseases including metabolic dysfunction-associated steatohepatitis (MASH), obesity and type 2 diabetes mellitus. The company develops DA-1241, a G-protein-coupled receptor 119 (GPR119) agonist that promotes release of gut peptides GLP-1, GIP and PYY, with positive preclinical effects on liver inflammation, lipid metabolism, weight loss, glucose control, hepatic steatosis, inflammation and fibrosis; DA-1241 has completed Phase 1 trials for type 2 diabetes and is in Phase 2a for MASH, with topline results expected in December 2024; and DA-1726, a dual oxyntomodulin analog agonist of glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) for once-weekly injection in obesity treatment. MetaVia, founded in 2014 and headquartered in Cambridge, Massachusetts, operates primarily in the United States with a focus on small-molecule therapeutics for cardiovascular and metabolic indications targeting patients with chronic liver and related metabolic diseases. In recent developments, the company changed its name from NeuroBo Pharmaceuticals to MetaVia Inc. and its ticker from NRBO to MTVA on November 29, 2024 ahead of key clinical milestones; completed a $10 million private placement in May 2025 extending its cash runway into 2026; and announced a 1-for-11 reverse stock split effective December 4, 2025 to maintain Nasdaq Capital Market listing compliance.
MetaVia Presents Higher-Dose Phase 1 Results for DA-1726 at EASL Congress 2026, Supporting Potential in Obesity and MASH
Why MetaVia Stock Is Surging On Friday?
Why MetaVia Stock Is Falling On Thursday?
MetaVia Highlights Peer-Reviewed Publication Supporting the Anti-Fibrotic Potential of Vanoglipel in MASH
MetaVia to Present Obesity Data at the American Diabetes Association's (ADA) 2026 Scientific Sessions
MetaVia Reports First Quarter 2026 Financial Results and Provides Corporate Update
MetaVia to Present Data Highlighting DA-1726, a GLP-1/Glucagon Dual Agonist, in a Late-Breaking Poster Presentation at the EASL Congress 2026
MetaVia Doses the First Patient in Higher-Dose Phase 1 Study of DA-1726, Its GLP-1 and Glucagon Dual Agonist for the Treatment of Obesity
MetaVia Reports Year End 2025 Financial Results and Provides Corporate Update
MetaVia Advances GLP-1-Based Obesity Program with IRB Approval for Higher-Dose Phase 1 Studies of DA-1726, a GLP-1 and Glucagon Dual Agonist Demonstrating Best-in-Class Potential for Weight Loss and Glucose Control
MetaVia Inc. (NASDAQ:MTVA) Short Interest Up 82.9% in February
MetaVia Expands Global Patent Protection for Vanoglipel, Supporting Metabolic and Liver Disease Therapy Through 2035
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Life Sciences Virtual Investor Forum
MetaVia to Highlight Novel Obesity and Metabolic Therapies at Upcoming Emerging Growth Conference
MetaVia Secures Dozens Of Patents Through 2041 For Obesity Drug
MetaVia Builds Comprehensive Global Patent Protection for DA-1726, Securing Exclusive Rights to Novel Obesity and Metabolic Therapy Through 2041
MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile